New Horizon Medical Solutions has announced a strategic collaboration with Soring, the U.S. affiliate of German medical technology company Söring, to distribute an ultrasonic wound debridement system designed to enhance wound care treatment. The partnership focuses on expanding access to the Söring Ultrasonic-Assisted Wound debridement system, which consists of an ultrasonic generator and instrument intended for cleansing chronic and acute wounds by removing fibrin tissues and breaking up biofilms. The technology targets various wound types including diabetic foot syndrome, decubitus ulcers, burns, post-surgical wounds, and post-traumatic wounds.
According to Jeffrey Alan Niezgoda, MD, Chief Medical Officer of Kent Imaging and board member of NHMS, combining the SONOCA 185 and UAW instruments with existing wound management technologies can significantly improve wound bed preparation and patient outcomes. "These devices synergistically optimize wound bed preparation prior to CAMPs application," Niezgoda stated regarding the integrated approach to wound care. Will Hall, CEO of New Horizon Medical Solutions, emphasized that the collaboration reflects the company's commitment to combining advanced technology with evidence-based clinical solutions. "By bringing Söring's ultrasonic system into our portfolio, we're expanding access to innovative tools that address critical gaps in treatment while improving efficiency and outcomes across care settings," Hall explained.
The partnership aims to enhance wound management capabilities in various medical environments through this technology integration. The Söring system represents specialized ultrasonic technology for tissue resection and ablation, developed by a company founded in 1985 and headquartered in Germany. According to company information available at https://www.soering.com, Söring focuses on making surgical procedures more efficient, safer, and easier to perform through intuitive user experience and direct service support. New Horizon Medical Solutions, known for its biologically derived human placental allograft products including amniotic membranes, placental tissues, and skin grafts, views this collaboration as expanding its advanced wound care technology portfolio.
The ultrasonic debridement system works by improving wound status and promoting healing through the removal of necroses, fibrin, scab, and pus. Medical professionals can learn more about wound care technologies through resources at https://www.nhmedical.com, though the companies emphasize they remain independent contracting parties without an agency relationship. This collaboration represents a significant development in wound care technology integration, potentially addressing treatment gaps in managing complex wounds across different healthcare settings. The technology's ability to break down biofilms and remove fibrin tissues makes it particularly valuable for chronic wounds that have proven resistant to conventional treatments, potentially reducing healing times and improving patient quality of life.
The strategic partnership between these two companies creates a more comprehensive wound care solution by combining ultrasonic debridement technology with existing biological products. This integrated approach could transform wound management protocols in hospitals, clinics, and long-term care facilities where complex wounds present ongoing challenges. By making this advanced technology more widely available, the collaboration addresses a critical need in healthcare for more effective wound treatment options, particularly for patients with diabetes, mobility issues, or surgical complications who are at higher risk for chronic wounds.
